Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Monoclonal Antibodies Report Part 1 (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 27/06/2007
- Report Title: Monoclonal Antibodies Report Part 1
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 369
Introduction
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
Scope
Comprehensive financial strategic analysis of the mAb market out to 2012
Global sales forecasts to 2012 for all marketed and Phase III mAb products
Analysis of market trends by product, company, therapy area, technology and target type
Analysis of characteristics of key products and insight into direction of mAb technology evolution and pipeline dynamics
Highlights
The overall ethical pharmaceutical market is expected to face a decline in sales over 2011 to 2012 as a result of the 'patent cliff'. The patent cliff will impact the small molecule market, in contrast, the mAb market segment will continue to record robust growth.
Over the period 2006-12, the mAb market segment will achieve a sales CAGR of 14.2% versus a small molecule sales CAGR of 0.6%. The main barrier to sales growth for small molecules is exposure to material generic competition, which will have no effect on mAbs out to 2012.
mAbs currently command a two-fold average revenue per product premium over small molecules. Positive factors supporting this premium include a higher demand due to addressing therapy areas of high unmet need and lower competitive intensity due to accessing novel target space.
Reasons to Purchase
Assess the key products that will drive sales growth in the mAb market to 2012
Understand the challenges and barriers to entry for new players seeking to venture into the mAb market
Understand the nature of the generic threat across different molecule types and the insulation of mAb products from biosimilars out to 2012
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
Scope
Comprehensive financial strategic analysis of the mAb market out to 2012
Global sales forecasts to 2012 for all marketed and Phase III mAb products
Analysis of market trends by product, company, therapy area, technology and target type
Analysis of characteristics of key products and insight into direction of mAb technology evolution and pipeline dynamics
Highlights
The overall ethical pharmaceutical market is expected to face a decline in sales over 2011 to 2012 as a result of the 'patent cliff'. The patent cliff will impact the small molecule market, in contrast, the mAb market segment will continue to record robust growth.
Over the period 2006-12, the mAb market segment will achieve a sales CAGR of 14.2% versus a small molecule sales CAGR of 0.6%. The main barrier to sales growth for small molecules is exposure to material generic competition, which will have no effect on mAbs out to 2012.
mAbs currently command a two-fold average revenue per product premium over small molecules. Positive factors supporting this premium include a higher demand due to addressing therapy areas of high unmet need and lower competitive intensity due to accessing novel target space.
Reasons to Purchase
Assess the key products that will drive sales growth in the mAb market to 2012
Understand the challenges and barriers to entry for new players seeking to venture into the mAb market
Understand the nature of the generic threat across different molecule types and the insulation of mAb products from biosimilars out to 2012
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
